The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.
Scott T. Tagawa
No relevant relationships to disclose
Naveed Hassan Akhtar
No relevant relationships to disclose
Joseph Osborne
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Shankar Vallabhajosula
No relevant relationships to disclose
Stanley J. Goldsmith
No relevant relationships to disclose
Renee Kahn
No relevant relationships to disclose
Caryn Ecker
No relevant relationships to disclose
Himisha Beltran
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Matthew I. Milowsky
No relevant relationships to disclose
Neil Harrison Bander
Consultant or Advisory Role - BZL Biologics
Stock Ownership - BZL Biologics
David M. Nanus
No relevant relationships to disclose